$885 Million is the total value of Sarissa Capital Management LP's 11 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALKS | ALKERMES PLC | $313,513,000 | -25.0% | 14,040,000 | 0.0% | 35.43% | -15.8% | |
| BIIB | BIOGEN INC | $171,681,000 | +30.9% | 643,000 | 0.0% | 19.40% | +47.0% | |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $169,800,000 | -10.1% | 16,390,000 | 0.0% | 19.19% | +0.9% | |
| GILD | Sell | GILEAD SCIENCES INC | $78,538,000 | -5.3% | 1,273,100 | -5.1% | 8.88% | +6.3% |
| INVA | INNOVIVA INC | $76,789,000 | -21.3% | 6,614,000 | 0.0% | 8.68% | -11.7% | |
| MRSN | Sell | MERSANA THERAPEUTICS INC | $27,020,000 | +36.0% | 3,997,010 | -7.0% | 3.05% | +52.8% |
| AMRN | AMARIN CORP PLCspons adr new | $26,158,000 | -26.8% | 23,998,000 | 0.0% | 2.96% | -17.9% | |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $17,524,000 | +19.1% | 1,390,790 | 0.0% | 1.98% | +33.8% | |
| VOR | VOR BIOPHARMA INC | $2,460,000 | -19.9% | 618,000 | 0.0% | 0.28% | -10.0% | |
| PEAR THERAPEUTICS INC | $1,021,000 | +32.4% | 500,356 | 0.0% | 0.12% | +47.4% | ||
| REGULUS THERAPEUTICS INC | $315,000 | -17.8% | 185,183 | 0.0% | 0.04% | -7.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.